FirstIgnite is supporting the commercialization of the University of Notre Dame’s gene therapy treatment technology. This treatment is aimed at addressing Non-ketotic Hyperglycinemia (NKH), a genetic disorder marked by unusually elevated levels of glycine. The innovative therapy utilizes a viral vector meticulously designed to target NKH resulting from defects in the glycine decarboxylase (GLDC) protein. Remarkably, GLDC protein defects account for a significant 80% of all NKH cases.
This technology is applicable to the treatment of Non-ketotic Hyperglycinemia patients, it has potential application in other glycine-related genetic disorders, and it can be integrated into the broader gene therapy market for genetic diseases. The global gene therapy market was worth $9 billion in 2022 and is projected to increase to $23.9 billion by 2028.
The University of Notre Dame’s gene therapy treatment technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the University of Notre Dame team, you can schedule a time directly on their team’s calendar here.